Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and Nab-paclitaxel in Advanced HNSCC
NCT03975270Phase 2Unknown
- Start
- Jul 2019
- Primary completion
- May 2021
- Countries
- 1
01
Overview
Phase 2, open-label trial of sintilimab in head and neck squamous cell carcinoma (HNSCC). Primary endpoint: Objective Response Rate at 2 years. Status: unknown.
02
Drugs
sintilimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03975270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03975270.